Taking people in ItalyNo phase
Follows adults with hip joint disease who receive the SMS femoral stem implant
Tracks how the SMS hip implant performs in adults with hip joint disease.
Key facts
- Who runs it
- Medacta International SA
- Where
- Milan, ItalySee the siteAlso in 3 other countries, 3 sites
- Trial code
- Registry title
- The Medacta International SMS Post-Marketing Surveillance Study
- Status
- Recruiting
- People taking part
- 550 people, planned
- Started
- Jul 2015
- Expected to end
- Jul 2032
- Type of study
- Observational
- Treatments tested
- SMS femoral stem
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with a painful or disabling hip joint who are scheduled for a first total hip replacement.
- Age
- 18 to 75 years, at the time of surgery.
- Sex
- All sexes can join.
- Disease stage
- Severely painful and/or disabling hip joint with osteoarthritis, traumatic arthritis, developmental dysplasia of the hip or avascular necrosis of the femoral head.
- Earlier treatment
- Scheduled for a primary total hip replacement.
Main reasons for not taking part
- Active infection
- Pregnancy
- Active rheumatoid arthritis
- Osteoporosis
- Mental illness that could affect consent or the 10 year follow-up
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Individuals with a severely painful and/or disabling hip joint with osteoarthritis, traumatic arthritis or developmental dysplasia of the hip or avascular necrosis of the femoral head
- In order to take part in this study, all study participants must be between the ages of 18 and 75 years of age, at the time of surgery
- Scheduled for a primary total hip replacement
Who cannot take part
- Osteomalacia where uncemented implant fixation is contraindicated
- Active infection
- Mental illness where the known condition is likely to compromise the patient's ability to consent, affect the patient's assessment of their progress or complete the 10 year cycle of follow-up appointments and reviews
- Metabolic disorders which may impair bone formation where uncemented implant fixation is contraindicated
- Muscular atrophy or neuromuscular disease
- Allergy to implant material
- Pregnancy
- Grossly distorted anatomy (surgeon's discretion)
- Active rheumatoid arthritis
- Osteoporosis
- Any patient who cannot or will not provide informed consent for participation in the study
- Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in Italy
Also in 3 other countries, 3 sites
- Istituto Ortopedico GalezziMilan, ItalyContact: Giuseppe Peretti, Prof.Taking people
About the trial
What the trial wants to find out
This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.
Treatments tested
- SMS femoral stem
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Medacta SMS Femoral Stem Component. A Multi-National, Multi-Centre, Clinical Surveillance Study
- Plain-language title
- Follows adults with hip joint disease who receive the SMS femoral stem implantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT02748408, who can take part
- Record updated
- 13 October 2026